initi guid conserv upsid
larg tie uncertain instr demand
sale yoy fx vs our/street est
core growth in-lin estimate gm
yoy due nasd manufactur site start-up cost opm came
yoy signific cost control mostli sg line help sustain margin
non-gaap ep y/i vs our/street est
continu acg/dgg out-performance lsag still lag
similar ytd perform agil saw broad-bas strength agil cross lab
acg diagnost genom dgg partial off-set weak
instrument-heavi life scienc appli lsag lsag continu affect
soft china condit food market lacklust chemic demand
much-anticip nasd nucleic acid solut divis manufactur site frederick
co saw initi revenu contribut help push nasd sale
year overal end-market perform came larg expect solid
pharma core challeng food soft chemic
typic agil key question much conservat
built core revenu growth guid vs estimate adj ep guid
vs our/street est view management state
noth fundament chang market see limit upsid given continu
soft commentari market wherea upsid come nasd strong
dgg/acg result like alreadi larg built-in expect
rais est po reiter neutral
adjust est model sale core
adj ep model revenu
core adj ep po move higher ebtida
base estimate in-lin peer due recent peer
group multipl expans reiter neutral rate see steadi end market
consum strong core portfolio solid execut believ valuat
alreadi reflect potenti upsid given current mix macro indic
full definit iqmethod sm measur see page
net dbt
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart santa clara california agil
technolog lead supplier analyt
instrument consum product
use mainli research qualiti assur
applic custom life scienc
chemic analysi industri compani
known leader life scienc
industri long histori innov
believ well posit
benefit secular posit growth trend
life scienc acquisit also
provid new opportun growth
under-penetrated market howev specif
end-market show sign volatil
see risk/reward balanc
po base ev/ebitda multipl in-lin agil life
scienc tool peer group believ justifi given agil margin expans
potenti upsid new gc product cycl macro improv solid organ
revenu growth outlook strateg option opportun capit deploy
risk po econom risk fx risk slower expect uptak new
product expans new market competit risk reduct spend
integr risk takeout specul overhang
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
